All In Biotech

Drug Trial Radar · NCT06162338

A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I

A Prospective, Single-center, Open-arm, Single-arm Study of the Safety and Preliminary Efficacy of Single Intravenous Infusion Administration of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I

Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

3

Planned (sponsor's estimate)

Start

Nov 15, 2023

Primary completion

Dec 17, 2026

Study completion Dec 17, 2031

Sponsor

Lead sponsor
He HuangAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lingyi Biotech Co., Ltd.
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective single-center, open, single-arm, single-dose intravenous infusion study to evaluate the safety and initial efficacy, pharmacodynamic characteristics, immunogenicity, biodistribution, and viral shedding of LY-M001 injection.This study mainly includes the main study stage and the long-term follow-up study stage.

Conditions

  • Gaucher Disease Type I

Interventions

  • LY-M001 InjectionBiological

    With 5.0 × 10\^12 vg/kg as the initial effective dose (first dose group), 1 to 2 subjects are expected to be included. The first dose group was enrolled by sentinel method, and the first subject in this group was observed for at least 28 days after receiving LY-M001 (dose-limited toxicity \[DLT\] observation period) to enroll the next subject. After the first participant completes the safety evaluation of dosing for at least 28 days, the investigator (PI) and the partner discuss the safety and efficacy data and decide to maintain the first dose or increase/reduce it to another dose group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment- related adverse eventsTime frame: within 38 weeks after LY-M001 infusion
  2. Incidence of events adjudicated as dose limiting toxicity (DLT)Time frame: within 28 days after LY-M001 infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hanzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.